AMX0035 Extension: Phase II Clinical Trial to Evaluate Safety, Tolerability, and Biomarker Engagement of AMX0035 in Patients with ALS

Grants and Contracts Details

StatusFinished
Effective start/end date2/28/173/14/19

Funding

  • Amylyx Pharmaceuticals Incorporated: $20,927.00